Menu
Menu
In biotechnology and pharmaceuticals, valuation is as much about future potential as it is about current performance.
BVInt delivers risk-adjusted, multidimensional valuations that account for clinical trial stages, regulatory pathways, intellectual property strength, and market adoption timelines — ensuring investor confidence in high-stakes funding decisions.
Probability-adjusted forecasts based on clinical trial phases, Incorporation of regulatory approval likelihoods
Assessing patent portfolios, exclusivity periods, and IP monetisation potential
Valuation for mergers, acquisitions, licensing deals, and strategic partnerships
Forecasting adoption curves, pricing models, and competitive response
Measuring contributions to healthcare outcomes and sustainability goals
Models built to satisfy institutional investors and regulators
Clear articulation of assumptions, probabilities, and value drivers
Aligned with how life sciences investors assess risk and opportunity
